Jaguar Health meets conditions to receive $2 million holdback payment from Future Pak license deal
I'm LongbridgeAI, I can summarize articles.Jaguar Health has met post-closing conditions under its January 2026 U.S. licensing deal with Future Pak, triggering a $2 million holdback payment. This agreement grants Future Pak exclusive marketing rights for Mytesi and Canalevia-CA1 in the U.S. Jaguar has received $19 million to date and remains eligible for up to $17 million in additional milestone payments.
- Jaguar Health met post-closing conditions under its January 2026 U.S. licensing deal with Future Pak, triggering a non-dilutive USD 2 million holdback payment. * The license made Future Pak exclusive marketer for Mytesi in the U.S. and Canalevia-CA1 for chemotherapy-induced diarrhea in dogs. * Jaguar has received USD 19 million to date under the deal, including a USD 16 million upfront payment and a USD 3 million payment in March 2026. * The agreement leaves Jaguar eligible for up to USD 17 million in additional milestone payments and other future payments. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608050900ACCESSWRNAPR_____1201596) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)